Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Howard Hughes Holdings to join S&P SmallCap 600 on Oct. 28
- Northrop Grumman wins $43.8M Navy contract for Trident II facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
